Strategic Acquisition Pixyl was acquired by Gleamer in March 2025, positioning it within a larger AI-driven radiology solutions ecosystem, which may facilitate cross-selling of complementary AI tools and integrated healthcare workflows.

Regulatory Milestones Having secured FDA 510(k) clearance for Pixyl.Neuro and CE-mark certification under the new Medical Device Regulations, Pixyl demonstrates strong regulatory progress, enhancing its appeal to healthcare providers seeking reliable, compliant neuroimaging AI solutions.

Innovative Recognition Being recognized as one of France’s most innovative companies highlights Pixyl’s technological edge and innovation capacity, making it attractive to forward-thinking hospitals and radiology centers seeking cutting-edge AI technologies.

Partnership Opportunities Existing partnerships with Brainomix, GE Healthcare, and AP-HP indicate an openness to collaborative growth; expanding these relationships or establishing new collaborations could open doors to larger clinical deployment channels.

Funding & Revenue With recent funding of $2.7M and revenue estimates under $1M, Pixyl offers an entry point for investors and clients interested in early-stage AI medical tech providers with scalable innovations in neuroimaging.